Undisclosed Antibody/ADC Program

About Frezent Biological Solutions

Frezent Biological Solutions is a private, preclinical-stage biotech founded in 2018 and based in San Diego, CA. The company is pioneering a novel approach to oncology by developing therapeutics that target dormant cancer cells, a key driver of aggressive and treatment-resistant recurrence. Its pipeline consists of antibodies and ADCs aimed at preventing the reactivation of these cells, addressing a significant unmet need for over 30 million cancer survivors worldwide. Frezent is actively seeking partnerships and funding to advance its programs toward clinical development.

Therapeutic Areas

Other Head and Neck Cancer Drugs